Value Viewpoint – recent developments in US healthcare value and access with Kimberly Westrich: July – August 2024

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from July and August 2024. What happened over these months that you were expecting? As expected, the Centers for Medicare & Medicaid Services (CMS) announced the prices for the 10 drugs selected for the Medicare Drug Price Negotiation Program (MDPNP). CMS has not provided a detailed explanation of how these prices were determined, leading many stakeholders to call for greater transparency in the agency’s decision-making process. As articulated by NPC’s President and CEO, John O’Brien, in a public statement: “[CMS] didn’t offer specifics...